Our animal model and clinical data also suggest that the lack of an observed ACE inhibition protective effect could be because the drug was started well after KTx due to concerns of hyperkalemia, reduced renal perfusion, hypotension, and anemia (84). This evidence concerns the gene ACE and anemia.